Analyst firms · Morgan Stanley · BDX
Morgan Stanley BDX price target and rating history
Becton Dickinson and Company (BDX) · Health Care
Morgan Stanley rates Becton Dickinson and Company (BDX) Overweight with a $295 price target, as of its latest action on May 30, 2023. It has published 3 rating actions on BDX since January 2022, including 0 upgrades and 0 downgrades. Across 6 firms with a BDX price target in the last 12 months, the median target is $191.
- Current rating
- Overweight
- Price target
- $295
- Median target, all firms
- $191
- Actions on BDX
- 3
Morgan Stanley price target on BDX
Every Morgan Stanley rating on BDX
- May 30, 2023
- Feb 4, 2022
- Jan 7, 2022
How other firms rate BDX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wells Fargo | Overweight | $242 | Nov 6, 2026 |
| Wolfe Research | Outperform | Oct 20, 2026 | |
| UBS | Buy | $19 | Jul 28, 2026 |
| Evercore ISI | Outperform | $180 | May 4, 2026 |
| Goldman Sachs | Neutral | $167 | Apr 10, 2026 |
| Barclays | Overweight | $202 | Feb 10, 2026 |
| Citigroup | Buy | $233 | Feb 3, 2026 |
Questions about Morgan Stanley and BDX
- What is Morgan Stanley's price target for BDX?
- Morgan Stanley's latest stated price target for Becton Dickinson and Company (BDX) is $295, from its action on May 30, 2023.
- What is Morgan Stanley's rating on BDX?
- Morgan Stanley rates BDX Overweight, a bullish rating, as of May 30, 2023.
- When did Morgan Stanley last change its view on BDX?
- On May 30, 2023, Morgan Stanley resumes coverage at Overweight, price target $295.
- How does Morgan Stanley's BDX target compare with other analysts?
- Across 6 firms with a BDX price target in the last 12 months, the median target is $191.
More BDX rating histories
All Morgan Stanley ratingsBDX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.